The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | ESMO 2018 Congress

Diffuse Large B-Cell Lymphoma MORE >>

Selinexor has been granted a fast track designation by the FDA for the treatment of patients with previously treated diffuse large B-cell lymphoma who are ineligible to receive high-dose chemotherapy with stem cell rescue or chimeric antigen receptor T-cell therapy.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.